Compound News and Research

RSS

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Researchers testing a vaginal microbicide based on a new type of anti-HIV drug found it provided monkeys significant protection against infection with a virus similar to HIV, according to a study reported at the International Microbicides Conference in Pittsburgh today.

24 May 2010

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.

21 May 2010

IGF1 drug improves nerve cell communication in PMS mouse model

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS).

21 May 2010

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS). Behavioral symptoms of PMS fall under the autism spectrum disorder category. The research will be presented Friday at the International Meeting for Autism Research (IMFAR) in Philadelphia.

21 May 2010

Smokers' breath contains 2,5-dimethylfuran

If you smoke, your breath contains 2,5-dimethylfuran. A team of Catalan researchers have proved that the presence of this chemical compound indicates that a person has smoked in the last three days. This substance does not appear in the breath of non-smokers, unless they have been in direct contact with tobacco smoke for a long time.

20 May 2010

GSK, EMBL-EBI, NLM and CDD collaborate to apply principles of open source to drug discovery for malaria

GlaxoSmithKline (GSK) had teamed up with leading public-domain data providers European Bioinformatics Institute (EMBL-EBI), the U.S. National Library of Medicine (NLM) and the U.S.-based informatics service provider Collaborative Drug Discovery (CDD) to make freely available key scientific information on more than 13,500 compounds that could ultimately lead to new treatments for malaria.

20 May 2010

BIOCIUS and Agilent launch RF360 High Resolution System for high-throughput screening of in vitro ADME assays

BIOCIUS Life Sciences, Inc. and Agilent Technologies Inc. today announced the launch of the RF360 High Resolution System for high-throughput screening of in vitro ADME assays. Combining the accurate mass capabilities of Agilent's time-of-flight (TOF) mass spectrometers and the unprecedented sample processing speed of RapidFire® technology, the instrument revolutionizes in vitro ADME analysis by eliminating the method development bottleneck in drug discovery.

From Evident Corporation - Life Sciences 20 May 2010

New study shows CDPK1 controls toxoplasma's ability to secrete microneme proteins

Researchers at Washington University School of Medicine in St. Louis have identified a parasite protein that has all the makings of a microbial glass jaw: it's essential, it's vulnerable and humans have nothing like it, meaning scientists can take pharmacological swings at it with minimal fear of collateral damage.

20 May 2010

MEDRAD's Intego PET Infusion System integrated with Pinestar's Nuclear Medicine Information System

Today, MEDRAD, Inc. and Pinestar Technology, Inc. announced plans to enable data communication between MEDRAD's Intego™ PET Infusion System and Pinestar's Nuclear Medicine Information System (NMIS). The companies are closing the information gap between state of the art infusion systems and the latest information systems, and thus adding to the workflow benefits of automated FDG infusion.

20 May 2010

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

Evotec AG today announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million.

19 May 2010

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Generex Biotechnology Corporation announced today publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. At the end of 2009, the Company announced positive interim results from a Phase II trial being conducted with AE37 in patients with breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 May 2010

BMJ News examines how drug resistance, access undermine malaria fight in Uganda, Cambodia

BMJ News looks at how lack of access to drugs and resistance are undermining the fight against malaria.

19 May 2010

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo.

19 May 2010

Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting

Among more than 5000 poster abstracts, Aprea AB has been selected to present a poster at the annual American Society of Clinical Oncology (ASCO) Meeting in Chicago. The presentation will describe the scientific rational and design of the ongoing phase I/II clinical trial with Aprea's drug candidate APR-246.

19 May 2010

Senesco Technologies third-quarter net loss increases to $5.28M

Senesco Technologies, Inc. today announced financial results for the three and nine months ended March 31, 2010.

18 May 2010

China Sky One Medical first-quarter total revenues increase 16.4% to $28.9 million

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced record financial results for the first quarter of 2010. Management is working diligently to finalize the amended Annual Report on Form 10-K for 2009.

18 May 2010

Aeterna Zentaris' AEZS-108 receives orphan medicinal product designation for ovarian cancer in Europe

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

17 May 2010

Scientists find clues to how our brains work

Scientists from The Scripps Research Institute have found a specific chemical compound secreted by many predators that makes mice behave fearfully. The research helps scientists better understand animal behavior, and may eventually lead to new insights into how sensory information is processed in human brains.

17 May 2010

Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections

The first clinical trials have started on a new investigational drug, discovered by researchers at Cardiff University, which is being developed to treat infections caused by Hepatitis C virus.

15 May 2010

Merck, Cardiome Pharma show superiority of BRINAVESS to amiodarone injection

In a new Phase III study, BRINAVESSTM (vernakalant) intravenous, an investigational compound being developed in the European Union by Merck (known as MSD outside the USA and Canada) and Cardiome Pharma Corp. to treat atrial fibrillation, showed that BRINAVESS was superior to amiodarone injection, in converting patients' heart rate from atrial fibrillation (AF) to sinus rhythm (SR) within 90 minutes of the start of administration.

15 May 2010

Compound News and Research

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

IGF1 drug improves nerve cell communication in PMS mouse model

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

Smokers' breath contains 2,5-dimethylfuran

GSK, EMBL-EBI, NLM and CDD collaborate to apply principles of open source to drug discovery for malaria

BIOCIUS and Agilent launch RF360 High Resolution System for high-throughput screening of in vitro ADME assays

New study shows CDPK1 controls toxoplasma's ability to secrete microneme proteins

MEDRAD's Intego PET Infusion System integrated with Pinestar's Nuclear Medicine Information System

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

BMJ News examines how drug resistance, access undermine malaria fight in Uganda, Cambodia

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting

Senesco Technologies third-quarter net loss increases to $5.28M

China Sky One Medical first-quarter total revenues increase 16.4% to $28.9 million

Aeterna Zentaris' AEZS-108 receives orphan medicinal product designation for ovarian cancer in Europe

Scientists find clues to how our brains work

Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections

Merck, Cardiome Pharma show superiority of BRINAVESS to amiodarone injection

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News